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I. Experimental Procedures 
 
General Unless otherwise noted, all chemicals and reagents were obtained from commercial 
suppliers (Sigma-Aldrich, VWR, Alfa Aesar) and used without further purification. Silica gel 
chromatography was carried out using AMD Silica Gel 60, 230-400 mesh. Synthetic reactions 
were monitored using thin layer chromatography (Merck 60 gel plates) using a UV-lamp for 
visualization. 1H and 13C NMR spectra were recorded on a Varian Inova 300 MHz or 500 MHz, 
or Bruker Prodigy 400 MHz instrument, in CDCl3 and are internally referenced to the residual 
solvent peak. Data for 1H NMR are reported as follows: chemical shift (δ ppm), multiplicity 
(s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, dd = doublet of doublets, 
dt = doublet of triplets, ddd = doublet of doublet of doublets), coupling constant (Hz), integration. 
High-resolution mass spectra were obtained at the California Institute of Technology Mass 
Spectrometry Facility.  
 
Chromatography. Analytical reversed-phase high-performance liquid chromatography (HPLC) 
was carried out using an Agilent 1200 series instrument with water and acetonitrile as mobile 
phases using an Agilent XDB-C18 column (4.6 x 150 mm, 5 µm). For quantitative HPLC analyses 
of reaction products, calibration curves using either 1,3,5-trimethoxybenzene or 1-phenyl-3-
propanol as internal standards were generated (Figures S11 to S20). Preparative-scale HPLC to 
purify enzymatic reaction products was performed using an Agilent XDB-C18 column 
(9.4 x 250 mm, 5 µm). The identity of enzymatic reaction products was confirmed by NMR 
analysis of products isolated from enzymatic reactions performed on preparative scale (vide infra). 
 
Cloning and site-saturation mutagenesis. Plasmid pET22b(+) (Novagen) with the pelB leader 
sequence removed was used as a cloning and expression vector for all constructs described in this 
study (see p. S39 for DNA sequences). Site-saturation libraries were generated using the 22c-trick 
method.1 Primers were obtained from IDT (primer sequences are available upon request). PCR 
was performed using Phusion polymerase (NEB) and the resulting PCR products were digested 
with DpnI (NEB), gel purified (Zymo Research), repaired using the method of Gibson,2 and used 
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to directly transform E. coli strain BL21(DE3) (Lucigen) by electroporation. Following 
electroporation, cells were recovered for 45 min at 37º C in Luria-Bertani (LB) medium, aliquots 
were plated on LB agar plates supplemented with 100 µg/mL ampicillin (LB-Amp plates), and 
plates were incubated at 37º C overnight. 
 
Site-saturation mutagenesis library screening in 96-well plate format. Single colonies of
 
E. coli BL21(DE3) cells transformed with cytochrome P411 site-saturation mutagenesis libraries 
(or cells transformed with plasmid encoding the corresponding P411 parent variant) were picked 
with sterile toothpicks and cultured in 96 deep-well plates in LB medium supplemented with 
100 µg/mL ampicillin (LB-Amp, 300 µL/well) at 37 ºC, 250 rpm, overnight. In a fresh 96 deep-
well plate, Hyperbroth medium (AthenaES, 950 µL/well, supplemented with 100 µg/mL
 
ampicillin (HB-Amp)) was inoculated with the pre-cultures (50 µL/well) and incubated at 37 ºC, 
250 rpm, for 2.5 h. The plates were cooled on ice for 20 minutes and then induced with 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and 1.0 mM 5-aminolevulinic acid (ALA) (final 
concentrations). Expression was conducted at 24 ºC, 200 rpm for 16-20 h. The cells were pelleted 
(3,000 g, 3 min), the supernatant was discarded, and the 96-well plates were transferred to an 
anaerobic chamber. Cell pellets were resuspended in reaction buffer (M9-N with 20 mM glucose, 
370 µL/well; M9-N minimal medium is 47.7 mM Na2HPO4, 22.0 mM KH2PO4, 8.6 mM NaCl, 
2.0 mM MgSO4, and 0.1 mM CaCl2, adjusted to pH 7.0 at room temperature), and stocks of indole 
(15 µL/well, in DMSO) and tosyl azide (15 µL/well, in DMSO) were added. Substrate 
concentration typically varied, depending on the reaction tested, between 10 and 15 mM for both 
indoles and tosyl azide (see Table S2). Following substrate addition, the plates were sealed with 
aluminum foil and shaken at 500 rpm, room temperature, overnight. After overnight incubation, 
the seal was removed and reactions were worked up for HPLC analysis: acetonitrile (typically 400 
to 600 µL/well) supplemented with internal standard was added, the plates were resealed, briefly 
mixed by vortexing, and incubated for 30 min to 1 h at room temperature. The plates were then 
centrifuged (5,000 g, 10 min), and the cleared supernatant was filtered through an AcroPrep 




Small-scale analytical amidation reactions using whole cells. Single colonies of E. coli 
BL21(DE3) cells transformed with plasmid encoding P411 variants were grown overnight in 3 mL 
LB-Amp medium at 37 ºC and 250 rpm. 2 mL of the pre-cultures were used to inoculate 48 mL of 
HB-Amp medium in 125 mL Erlenmeyer flasks. Cultures were incubated at 37 ºC, 230 rpm for 
2 h, typically reaching an OD600 = 1.5. Cultures were then cooled on ice (20 min) and induced with 
0.5 mM IPTG and 1.0 mM ALA (final concentrations). Expression was conducted at 24 ºC, 
130 rpm, for 16-18 h. Cultures were then cooled on ice, centrifuged (3,000 g, 3 min, 4 ºC), and the 
pellets were resuspended to OD600 = 30 in M9-N minimal medium. To determine P411 expression 
levels, aliquots of the cell suspension were subjected to the carbon monoxide binding spectroscopy 
assay specified below. 
Small-scale biocatalytic reactions were set up in 2 mL crimp vials with 400 µL reaction volume. 
Typically, 380 µL of P411-expressing cells at OD600 = 30 in M9-N buffer were added to the vials 
and transferred into an anaerobic chamber (no sparging of cell suspensions with argon was 
conducted; transfer of the cell solution to the anaerobic chamber, including several cycles of 
applying vacuum and purging with N2, proved sufficient for degassing). Inside the anaerobic 
chamber, the vials were put on a shaker (500 rpm), and 10 µL of indole stock solution (in DMSO) 
were added, followed by 10 µL of tosyl azide stock solution (in DMSO). Final concentrations, 
depending on the substrates tested, typically ranged from 10 to 25 mM indole and 10 to 25 mM 
tosyl azide, with 5 % co-solvent. For aerobic reactions, reactions were set up as specified above 
on the bench under standard atmosphere. For reactions aimed at analyzing indole-azide 
cycloaddition, a slightly modified protocol was employed: 360 µL cell suspension were used, and 
40 µL of a pre-mixed indole and tosyl azide substrate stock (in DMSO) was added. Following 
addition of substrates, the vials were sealed and shaken at room temperature, 500 rpm for 6–16 h. 
For sample work-up for HPLC analysis the reactions were quenched by adding acetonitrile 
(400 µL), samples were mixed thoroughly and incubated for 30 min. Subsequently, 200 µL of this 
mixture were transferred to fresh 1.5 mL tubes, and 800 µL acetonitrile supplemented with internal 
standards (1,3,5-trimethoxybenzene or 1-phenyl-3-propanol) was added. This double dilution 
protocol was employed to assure sample absorption on the HPLC remained in the linear range. 
Sample solutions in the 1.5 mL tubes were then centrifuged at 13,000 g for 10 minutes, the cleared 
supernatant was transferred to clean 2 mL vials and analyzed by HPLC. 
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Determination of whole-cell reaction kinetics and initial rates. Kinetics of 1-methylindole 
amidation were determined using whole E. coli cells expressing P411 variants. Reactions were set 
up as described above (Small-scale analytical amidation reactions using whole cells). Following 
addition of substrates, reactions were quenched at defined time points by addition of 400 μL 
acetonitrile, followed by vigorous mixing. The vials were removed from the anaerobic chamber 
and further sample work-up and HPLC analysis was performed as described above. 
 
Preparative scale reactions. E. coli BL21(DE3) cells freshly transformed with plasmid encoding 
P411 variants were grown overnight in 25 mL LB-Amp (37 ºC, 250 rpm). Next, 500 mL HB-Amp 
medium in a 2.8 L flask was inoculated with 20 mL of the pre-culture and incubated at 37 ºC, 
230 rpm for 2 h (to OD600 ca. 1.5). Cultures were then cooled in an ice-water bath for 20 min and 
induced with 0.5 mM IPTG and 1.0 mM ALA (final concentrations). Expression was conducted 
at 24 ºC, 140 rpm, for 16–20 h. Cultures were then centrifuged (5,000 g, 5 min, 4 ºC) and the cell 
pellets were resuspended to OD600 = 50 in M9-N buffer supplemented with 20 mM glucose 
(typically yielding ca. 110 mL of cell suspension). Aliquots of the cell suspension (4 mL) were 
used to determine the P411 expression level after cell lysis by sonication. Aliquots of the cell 
suspension (46 mL) were then transferred to 100 mL Erlenmeyer flasks and degassed by sparging 
with argon for at least 30 minutes. The reaction flasks were then transferred into an anaerobic 
chamber and indole stock solution (2 mL, in DMSO) and tosyl azide (2 mL, in DMSO) were added. 
Final concentrations were typically 10 to 20 mM indole and 10 to 20 mM tosyl azide, with 8% co-
solvent. The flasks were sealed with parafilm, removed from the anaerobic chamber, and shaken 
at room temperature, 100 rpm for 18 h. The reactions were quenched by adding acetonitrile 
(50 mL), transferred to two 50 mL tubes, and then centrifuged (4,000 g, 10 min). The supernatant 
was concentrated in vacuo to remove acetonitrile and extracted with EtOAc or 1:1 
EtOAc:cyclohexane (3 x 25 mL). The organic layers were washed with brine (20 mL), dried over 
MgSO4, filtered, concentrated, and purified by silica gel chromatography on a Biotage Isolera 
instrument. For several reactions, silica flash chromatography did not succeed to separate indole 
amidation products from tosyl sulfonamide; in these cases, preparative HPLC on an Agilent XDB-




Determination of P411 concentration. Aliquots (4 mL) of the same E. coli cell suspensions used 
for whole-cell biocatalytic reactions were lysed by sonication (QSonica instrument, 1 min 
sonication time, 1 s on/off cycles, 40 % output). 1 mL aliquots of the cell lysate were cleared by 
centrifugation (13,000 g, 10 min, 4°C), and the concentration of P411 enzymes in the lysate was 
determined from ferrous carbon monoxide binding difference spectra3 using the previously 
reported extinction coefficient for serine-ligated enzymes (ε = 103,000 M–1 cm–1).4 The 
concentration of purified P411 enzymes was determined by quantifying the amount of free hemin 
using the pyridine/hemochrome assay using the corresponding extinction coefficient 
(ε = 191,500 M–1 cm–1).5 
 
Protein purification. E. coli BL21(DE3) cells freshly transformed with plasmid encoding P411 
variants were grown overnight in 25 mL LB-Amp (30 ºC, 250 rpm). Next, 500 mL HB-Amp 
medium in a 2.8 L flask was inoculated with 20 mL of the pre-culture and incubated at 37 ºC, 
230 rpm for 2 h (to OD600 ca. 1.5). Cultures were then cooled in an ice-water bath for 20 min and 
induced with 0.5 mM IPTG and 1.0 mM ALA (final concentrations). Expression was conducted 
at 24 ºC, 140 rpm, for 16–20 h. Cultures were then centrifuged (5,000 g, 10 min, 4 ºC) and the cell 
pellets were frozen at –20 ºC. For protein purification, frozen cells from two such cultures were 
resuspended in buffer A (25 mM tris, 20 mM imidazole, 100 mM NaCl, pH 7.5, 4 mL buffer per 
gram of cell wet weight), supplemented with one protease inhibitor tablet (Roche), 1 mg/mL 
lysozyme, and 0.1 mg/mL DNAse I. The cell suspensions were lysed by sonication (1 min 
sonication time, 1 s on/off cycles, 40 % output). To pellet insoluble material, cell lysates were 
centrifuged (20,000 g, 20 min, 4 ºC), followed by filtering the cleared lysate through a 2 µM cut-
off syringe-driven filter unit. P411 proteins were purified from the cleared lysate using a nickel 
NTA column (1 mL HisTrap HP, GE Healthcare) using an AKTAxpress purifier FPLC system 
(GE Healthcare). P411 enzymes were eluted on a linear gradient from 100% buffer A to 100% 
buffer B (25 mM tris, 300 mM imidazole, 100 mM NaCl, pH 7.5) over 10 column volumes. 
Fractions containing eluted protein were pooled and subjected to three rounds of buffer exchange 
to storage buffer (25 mM Tris-HCl, 100 mM NaCl, pH 7.5) using centrifugal spin filters (10 kDa 
molecular weight cut-off, Amicon Ultra). Subsequently, the concentrated protein was aliquoted, 
flash-frozen on powdered dry ice, and stored at –80 ºC. Protein concentrations were determined 
using the pyridine/hemochrome assay specified above. 
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Amidation reactions using purified protein. Portions of M9-N buffer (290 µL) and NADPH 
(40 µL, 50 mM in M9-N), or multiples thereof, were combined in a 6 mL crimp vial and degassed 
by sparging with argon for at least 30 minutes. Purified protein solutions were adjusted to 20 µM 
in M9-N. After degassing was complete, the M9-N/reductant solution and purified protein stocks 
were brought into the anaerobic chamber. Reactions were set up on a 400 µL scale in 2 mL crimp 
vials: first, 340 µL of the M9-N/NADPH solution were added per vial, followed by 40 µL of 
purified P411 solution. Next, 10 µL of indole stock solution (in DMSO) were added, followed by 
10 μL of tosyl azide stock solution (in DMSO). Final concentrations were typically 5 mM indole, 
5 mM tosyl azide, 5 mM NADPH, and 2 μM P411, with 5% co-solvent. To assess tosyl azide 
reduction rates, reactions were set up as above but without addition of indole; the volume of M9-N 
buffer was adjusted accordingly to yield a total reaction volume of 400 μL. The vials were sealed, 
removed from the anaerobic chamber, and shaken at room temperature, 400 rpm for 1 to 6 h. The 
reactions were quenched by adding acetonitrile (400 μL) supplemented with internal standard. 
This mixture was transferred to a 1.5 mL tube and centrifuged at 13,000 g for 10 minutes. The 
supernatant was transferred to 2 mL vials and analyzed by HPLC. 
 
Assessment of electron transfer rates with the cytochrome c reduction assay. Electron transfer 
rates from NADPH through the reductase domain were assessed as described.3 First, 920 μL of 
0.1 M potassium phosphate buffer (KPi), pH 8.0, were transferred to a 1 cm pathlength 
spectrophotometric cuvette. Next, 50 μL of a 10 mg/mL solution of horse heart cytochrome c 
(Sigma-Aldrich; in 0.1 M KPi, pH 8.0) were added, followed by 10 μL of purified P411 variant 
(pre-diluted 20 to 800-fold in 0.1 M KPi, pH 8.0; purified P411 stock solutions are typically 100 
to 300 μM). The cuvette was sealed with parafilm, gently inverted a few times to mix, and baseline 
absorption at 550 nm was recorded for 1 to 2 min in a spectrophotometer in kinetic mode. Next, 
20 μL of 5 mM NADPH (in 0.1 M KPi, pH 8.0) were added, the cuvette was inverted a few times 
to mix, and absorption was recorded immediately for an additional 2 to 5 minutes (as long as the 
increase in absorption remained linear). Several dilutions were tested for each P411 variant. The 
resulting data were analyzed as described, using the extinction coefficient of reduced cytochrome 




Synthesis of amidation or cycloaddition authentic product standards. All authentic amidation 
or cycloaddition product standards used in this study (see Figure 4, main text) were synthesized 
by preparative-scale enzymatic reactions (see Preparative scale reactions, p. S5). Authentic 
standard of tosyl sulfonamide 4 was commercially available (Sigma-Aldrich).   
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II. Supplementary Tables 
Table S1: Hemoprotein variant testing for 1-methylindole amidation. 
 
 
Varianta Description, mutation, references Yield 3a Yield 4 Yield 5a 
Heminb Free hemin in M9-N buffer 1.2 52 0.3 
E. coli BL21(DE3) 
Whole E. coli cells, no 
heterologous protein 
overexpression 
1.7 40 0.4 
P450-BM3 
Wild-type P450-BM3 from 
Bacillus megaterium 
1.6 30 0.5 
P450-BM3 T268A 
C400S 
P450-BM3 with mutations T268A 
and C400S6 
1.7 30 0.5 
P450-CIS 
P450-BM3 with mutations V78A 
F87V P142S T175I A184V S226R 
H236Q E252G T268A A290V 
L353V I366V E442K7 
1.7 28 0.5 
P411-CIS 
P450-BM3 with mutations V78A 
F87V P142S T175I A184V S226R 
H236Q E252G T268A A290V 
L353V I366V C400S E442K6 
2.1 43 0.4 
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Varianta Description, mutation, references Yield 3a Yield 4 Yield 5a 
P450 HStar H92N 
H100N 
P450-BM3 with mutations V78M 
H92N H100N L181V T268A 
C400H L437W8,9 
1.6 31 0.6 
P411-HF 
P411-CIS with mutations V87T 
H92F L181G N201S L215Q 
I263M V281L T438C K472T 
N573D F646S Q674* 
1.9 34 0.5 
CYP119 
CYP119 from Sulfolobus 
acidocaldarius10 
1.8 30 0.6 
P450-CAM 
P450-CAM from Pseudomonas 
putida11 
1.7 33 0.5 
 
a Reactions were performed on 400 µL scale with whole E. coli cells expressing the respective 
hemoprotein variants, at 10 mM substrate loading (1-methylindole and tosyl azide). Results are 
the average of duplicate reactions. n.d. = not detected. b Reaction with hemin: in the anaerobic 
chamber, 10 µL of hemin solution (2 mM in DMSO) were added to 350 µL of argon-sparged 
M9-N buffer, followed by 20 µL of sodium dithionite as reductant (100 mM in M9-N buffer), 
1-methylindole (10 μL, 400 mM in DMSO) and tosyl azide (10 μL, 400 mM in DMSO). Final 
concentrations were 50 μM hemin, 5 mM sodium dithionite, 10 mM 1-methylindole and 10 mM 
tosyl azide with 5 % co-solvent.  
S11 
 
Table S2. Summary of directed evolution for indole amidation. 
Round Parent variant Libraries 
evaluateda 
Screening substrates Mutations 
identified 
1 P411-CIS (P) I263X 
1-methylindole (10 mM), 
tosyl azide (10 mM) 
I263Y 
2 P-I263Y T438X 
1-methylindole (10 mM), 
tosyl azide (10 mM) 
T438S 
3 P-I263Y T438S 
V87X, L181X, 
A328X 
1-methylindole (10 mM), 







1-methylindole (10 mM), 






1-methylindole (15 mM), 









1-methylindole (15 mM), 





indole (10 mM), tosyl 
azide (10 mM), screen 





indole (10 mM), tosyl 
azide (10 mM), screen 
for cycloaddition 
W82Fc 
7c P-I263Y T438S 
A82X, V87X, 
L181X 
1-methylindole (10 mM), 
tosyl azide (10 mM), 




aFinal variant for 1-methylindole amidation: P411-IA = P411-CIS I263Y T438S A328V 
A82W A268G W1046P 
bVariant for indole amidation: P411-IA W82C 
cVariant for indole-azide cycloaddition: P411-IA W82F 
dVariant for 1-methylindole-azide cycloaddition: P411-CIS I263Y T438S A82S 
 
 
Table S3: Tabulation of data shown in Figure 2 (main text). 














2.9 ± 1.2 n.a.b 
43.2 
±2.9 
n.a. 1.0 ± 0.3 n.a. 3:43:1 
P411-CIS (P) 





4147      
± 1197 










2923      
± 749 
4.0 ± 0.2 
478         
± 172 
1:6:1 
P-I263Y T438S 10.9 ± 
2.9 


































1237      
± 55 














1198      
± 241 







8413      
± 1024 
8.6 ± 2.2 
941         
± 331 
0.7 ± 0.1 77 ± 16 110:12:1 
 
a Assays were performed with 25 mM substrate loading. 
b n.a., not applicable. 
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Table S4: Tabulation of data shown in Figure 4 (main text). 
 
Variant 3 Yield (%) 
Amidation 
4 Yield (%) 
TsNH2 




P411-IA 78 (3a)a 8.6a 0.7 (5a)a 110:12:1 
P411-IA W82C 45 (3b) 5.3 12 (5b) 9:1:2 
P411-IA 81 (3c) 18 n.d.b 4:1 (3c:4) 
P411-IA 76 (3d) 22 n.d.b 3:1 (3d:4) 
P411-IA 91 (3e) 7 n.d.b 12:1 (3e:4)  




8.0 (3a) 59 24 (5a) 1:7:3 
P411-IA W82F 2.0 (3b) 5.2 16 (5b) 1:3:8 
 
a Assays were performed with 25 mM substrate loading; all other reactions were performed at 
10 mM substrate loading. 





III. Supplementary Figures 
 
Figure S1: Exemplary HPLC trace for enzymatic whole-cell amidation reactions with 
1-methylindole and tosyl azide. 
 
 
Shown is a HPLC trace obtained from whole-cell reactions performed with variant P411-CIS 
I263Y T438S (P-YS; see Figure 2 and Table S3). Whole cell reaction mixtures were worked up 
with acetonitrile and analyzed on an Agilent XDB-C18 column (4.6 x 150 mm, 5 µm), using water 
and acetonitrile as mobile phase (HPLC method: 50% acetonitrile starting concentration, 50% to 
80% acetonitrile over 7 min; 80% to 100% acetonitrile over 0.5 min; 100% acetonitrile for 
0.5 min). The identity of all relevant peaks is indicated; 1,3,5-trimethoxybenzene was used as 





Figure S2: Position of heme domain mutations in P411-CIS YSVWG. 
 
(A) Overall structure of the P411-CIS heme domain (pdb: 4H23),6 with residues mutated in 
P411-CIS YSVWG (P-YSVWG) shown as sticks and highlighted in blue; the heme cofactor is 




Figure S3: Reductase domain engineering to decrease nitrene reduction. 
 
(A) Schematic overview of P411 domain structure and mutants tested to reduce unproductive 
nitrene reduction. (B) Yield of P-YSVWG and reductase mutants in whole-cell amidation 
reactions; point mutant W1046P proved superior in reducing formation of sulfonamide 4, 
improving the ratio between amidation and nitrene reduction ca. 1.4-fold compared to P-YSVWG.  
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Figure S4: Position of the W1046P mutation in the P450-BM3 FAD domain. 
 
Crystal structure of the P450-BM3 FAD domain (pdb: 4DQK).12 The FAD cofactor is shown as 




Figure S5: P411-catalyzed 1-methylindole amidation in vitro. 
 
 
1-methylindole amidation reactions were performed in vitro using purified P411 variants. 
Reactions were set up at 5 mM substrate loading with 5 mM NADPH as reducing agent and with 




Figure S6: P411-catalyzed tosyl azide reduction in vitro. 
 
Tosyl azide reduction catalyzed by P411 variants was analyzed by setting up reactions in vitro 
using purified enzyme (2 µM) in absence of a nitrene acceptor substrate. Reactions were analyzed 
after 30 or 120 minutes; the HPLC yields of sulfonamide 4 are shown. P411-IA showed the lowest 
rates of nitrene reduction / sulfonamide formation, in agreement with the theory that the W1046P 
mutation slows down electron transfer and thus nitrene reduction. Of note, variant P-YSVWG, 
identical with P411-IA but lacking the W1046P mutation, showed slightly reduced sulfonamide 
formation rates compared to the parent variant P411-CIS, indicating that the accumulated heme 
domain mutations (I263Y T438S A328V A82W A268G) may have a minor effect on nitrene 
reduction rate. The 30-minute time point was used to calculate rates of nitrene reduction shown in 




Figure S7: Effect of W1046P in P411-CHA catalyzed C‒H amidation. 
 
 
To analyze whether the W1046P mutation represents a generalizable solution to improve activity 
of P411 nitrene transferases, we cloned the W1046P variant of P411-CHA, an enzyme previously 
evolved to catalyze amidation of C(sp3)-H bonds.13 We compared the two enzymes in the 
amidation of ethyl benzene, and found that the W1046P mutation delivered a slight increase in 




Figure S8: P411-IA catalyzed 1-methylindole amidation under aerobic conditions. 
 
Comparison of P411-IA whole-cell amidation reactions under anaerobic (left column) and aerobic 
(right column) conditions. The standard protocol for setting anaerobic reactions is provided in SI 
section I, Experimental Procedures, p. S4. Aerobic reactions were set up on the bench under 
standard atmosphere without prior degassing of cells or substrates. Reaction yields and TTN for 
amidation product 3a are given, showing a ca. 7-fold reduction in enzymatic amidation activity in 




Figure S9: Unprotected indole amidation by P411-IA W82C. 
 
 
P411-IA showed only low amidation activity on indole 2b to yield product 3b (7% yield, 
270 TTN); curiously, the enzymatic reaction predominantly delivered the indole-azide 
cycloaddition product 5b. However, screening of site-saturation mutagenesis libraries at positions 
W82, L181, and V328 delivered P411-IA W82C, showing ca. 6-fold higher yields of the desired 
indole amidation product 3b. This variant may provide a starting point for further evolution of 








To test whether the observed indole-azide cycloaddition activity was indeed susceptible to P411 
active site mutations and could thus potentially be targeted by directed evolution, we performed 
one additional round of site-saturation mutagenesis and screening. Variant P411-YS, providing the 
highest yields of cycloaddition product 5a within the P411-IA lineage (Figure 2), was randomized 
at positions W82, V87, and L181 (Table S2), and libraries were screened with 1 and 2a for 
enhanced cycloaddition activity. This delivered P-YS A82S, showing higher yield and TTN in the 
formation of 5a. Similarly, P411-IA site-saturation libraries of positions W82, L181, and V328 
were screened with 1 and 2b for formation of 5b, which delivered P411-IA W82F, showing 
enhanced cycloaddition activity. While this indicates that P411 indole-azide cycloaddition activity 
is evolvable and that the reaction takes place within or close to the P411 active site, further work 









Column: Agilent XDB-C18 
Standard: 1,3,5-trimethoxybenzene 
Wavelength: 230 nm 
 
 





Column: Agilent XDB-C18 
Standard: 1,3,5-trimethoxybenzene 
Wavelength: 230 nm 
 
 





Column: Agilent XDB-C18 
Standard: 1,3,5-trimethoxybenzene 




























Y = 5.955*X + 0
























Y = 2.377*X + 0
























Y = 3.476*X + 0
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Column: Agilent XDB-C18 
Standard: 1-phenyl-3-propanol 
Wavelength: 260 nm 
 
 





Column: Agilent XDB-C18 
Standard: 1-phenyl-3-propanol 
Wavelength: 260 nm 
 
 





Column: Agilent XDB-C18 
Standard: 1-phenyl-3-propanol 
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Y = 3.356*X + 0
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Column: Agilent XDB-C18 
Standard: 1,3,5-trimethoxybenzene 
Wavelength: 230 nm 
 
 





Column: Agilent XDB-C18 
Standard: 1,3,5-trimethoxybenzene 
Wavelength: 230 nm 
 
 





Column: Agilent XDB-C18 
Standard: 1,3,5-trimethoxybenzene 
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Y = 3.814*X + 0
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Column: Agilent XDB-C18 
Standard: 1,3,5-trimethoxybenzene 





























Y = 4.782*X + 0
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IV. Characterization of Reaction Products 
 
 
4-methyl-N-(1-methyl-1H-indol-2-yl)benzenesulfonamide 3a. Obtained as a light tan solid. 1H 
NMR (400 MHz, CDCl3) δ 7.68 – 7.58 (m, 2H), 7.25 – 7.22 (m, 1H), 7.20 – 7.13 (m, 3H), 7.06 – 
7.01 (m, 2H), 6.96 (br s, 1H), 3.74 (s, 3H), 2.37 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 143.43, 
136.80, 135.22, 129.41, 127.37, 126.53, 124.45, 122.16, 119.77, 117.44, 110.44, 109.42, 31.96, 
21.51. HRMS (FAB+) exact mass calculated for C16H16N2O2S




4-methyl-3-tosyl-3,4-dihydro-[1,2,3]triazolo[4,5-b]indole 5a. Obtained as a light pink solid. 1H 
NMR (400 MHz, CDCl3) δ 7.92 – 7.85 (m, 2H), 7.32 – 7.26 (m, 3H), 7.25 – 7.17 (m, 2H), 7.09 
(dt, J = 7.9, 0.9 Hz, 1H), 3.46 (s, 3H), 2.42 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 155.32, 142.45, 
140.12, 134.26, 129.35, 126.33, 125.89, 123.02, 118.97, 116.88, 109.70, 29.06, 21.51. HRMS 
(FAB+) exact mass calculated for C16H15N4O2S
+ requires m/z 327.0916, found 327.0937. 
Characterization data is consistent with prior reported data and supports the assignment of the 
regiochemistry of the cycloaddition product.14 
 
 
N-(1H-indol-2-yl)-4-methylbenzenesulfonamide 3b. Obtained as a colorless solid. 1H NMR 
(400 MHz, CDCl3) δ 8.04 (br s, 1H), 7.67 – 7.58 (m, 2H), 7.32 – 7.28 (m, 1H), 7.19 – 7.11 (m, 
5H), 7.03 – 6.94 (m, 1H), 6.20 (s, 1H), 2.36 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 143.50, 136.59, 
S29 
 
134.38, 129.42, 127.39, 124.01, 122.73, 121.66, 120.31, 117.45, 112.41, 111.38. HRMS (FAB+) 
exact mass calculated for C15H15N2O2S




3-tosyl-3,4-dihydro-[1,2,3]triazolo[4,5-b]indole 5b. Obtained as a colorless solid. 1H NMR (400 
MHz, CDCl3) δ 7.90 – 7.84 (m, 2H), 7.32 – 7.20 (m, 4H), 7.20 – 7.10 (m, 2H), 2.41 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 159.70, 142.95, 139.48, 138.93, 132.37, 129.43, 126.34, 126.31, 
123.48, 118.01, 116.57, 111.66, 21.52. HRMS (FAB+) exact mass calculated for C15H13N4O2S
+ 
requires m/z 313.0759, found 313.0766. 
 
 
N-(1,5-dimethyl-1H-indol-2-yl)-4-methylbenzenesulfonamide 3c. Obtained as a white solid. 1H 
NMR (400 MHz, CDCl3) δ 7.68 – 7.60 (m, 2H), 7.21 – 7.15 (m, 2H), 7.12 (d, J = 8.4 Hz, 1H), 
6.99 – 6.94 (m, 2H), 6.69 (br s, 1H), 6.09 (s, 1H), 3.70 (s, 3H), 2.38 (s, 3H), 2.27 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 143.38, 136.92, 133.73, 129.37, 129.08, 127.53, 126.80, 124.77, 123.80, 
117.09, 109.78, 109.09, 32.97, 21.47, 21.19. HRMS (FAB+) exact mass calculated for 
C17H19N2O2S
+ requires m/z 315.1167, found 315.1168. 
 
 
N-(5-methoxy-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide 3d. Obtained as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.61 (m, 2H), 7.22 – 7.15 (m, 2H), 7.12 (d, J = 8.9 Hz, 
1H), 6.97 (s, 1H), 6.79 (dd, J = 8.8, 2.4 Hz, 1H), 6.39 (d, J = 2.4 Hz, 1H), 6.22 (br s, 1H), 3.70 (s, 
3H), 3.63 (s, 3H), 2.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 154.31, 143.38, 137.07, 130.54, 
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129.43, 127.50 (two overlapping signals, confirmed by HSQC), 125.09, 112.99, 110.39, 109.82, 
98.53, 55.40, 33.10, 21.47. HRMS (FAB+) exact mass calculated for C17H19N2O3S
+ requires m/z 
331.1116, found 331.1137. 
 
 
N-(6-methoxy-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide 3e. Obtained as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 7.69 – 7.60 (m, 2H), 7.21 – 7.11 (m, 2H), 6.97 – 6.85 (m, 
2H), 6.67 (d, J = 2.1 Hz, 1H), 6.62 (dd, J = 8.7, 2.2 Hz, 1H), 6.31 (br s, 1H), 3.83 (s, 3H), 3.66 (s, 
3H), 2.37 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 156.64, 143.42, 136.79, 136.00, 129.44, 127.41, 
125.07, 118.83, 118.42, 110.63, 109.97, 92.65, 55.65, 32.97, 21.55. HRMS (FAB+) exact mass 
calculated for C17H19N2O3S
+ requires m/z 331.1116, found 331.1131. 
 
 
N-(6-chloro-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide 3f. Obtained as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 7.64 – 7.58 (m, 2H), 7.24 (dd, J = 1.6, 0.7 Hz, 1H), 7.18 (m, 
1H), 7.01 (d, J = 0.9 Hz, 1H), 6.93 (m, 2H), 6.14 (br s, 1 H), 3.70 (s, 3H), 2.38 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 143.63, 136.60, 135.59, 129.49, 128.33, 127.34, 127.25, 123.11, 120.59, 
118.55, 110.76, 109.56, 33.08, 21.54. HRMS (FAB+) exact mass calculated for C16H16N2O2SCl
+ 


















































VI. Nucleotide and amino acid sequence of P411-IA constructs 





















































































DNA sequence of P411-IA in expression plasmid pET22b+ 
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